Morphine and related drugs, which are the most effective analgesics for the relief of severe pain, act through activating opioid receptors. The endogenous ligands of these receptors are opioid peptides which cannot be used as antinociceptive agents due to their low bioactivity and stability in biological fluids. The major goal of opioid research is to understand the mechanism of action of opioid receptor agonists in order to improve therapeutic utility of opioids. Analgesic effects of morphine are mediated mostly through activation of the mu opioid receptor. However, in the search for safer and more effective drug candidates, analogs with mixed opioid receptor profile gained a lot of interest. Recently, the concept of biased agonists able to differentially activate GPCR downstream pathways, became a new approach in the design of novel drug candidates. It is hypothesized that compounds promoting G-protein signaling may produce analgesia while β-arrestin recruitment may be responsible for opioid side effects. In this report we showed that replacement of the tyrosine residue in the muselective ligand Tyr-c[D-Lys-Phe-Asp]NH 2 with 2′,6′-dimethyltyrosine (Dmt) produced a cyclopeptide Dmt-c[DLys-Phe-Asp]NH 2 with mu/delta opioid receptor agonist profile. This analog showed improved antinociception in the hot-plate test, probably due to the simultaneous activation of mu and delta receptors but also significantly inhibited the gastrointestinal transit. Using the bioluminescence resonance energy transfer (BRET) assay it was shown that this analog was a mu receptor agonist biased toward β-arrestin. β-Arrestin-dependent signaling is most likely responsible for the observed inhibition of gastrointestinal motility exerted by the novel cyclopeptide.
Introduction
Centrally acting opioid agonists, such as morphine, are the most widely used analgesics for the treatment of severe pain [1] . Among the three types of classic opioid receptors, mu, delta and kappa, the mu receptor was identified as the one responsible primarily for the painrelieving effects but also for a number of undesired side effects, including sedation, respiratory depression, inhibition of gastrointestinal transit and also development of tolerance and physical dependence [2] .
In the previous decades, extensive structure-activity relationship studies of opioid receptor ligands concentrated on the obtaining analogs with high selectivity for one opioid receptor type. More recently, the development of compounds with mixed opioid profile is gaining a lot of interest [3, 4] . Several opioid analogs with peptide or alkaloid structure that represent this new strategy have already been synthesized and evaluated in vitro and in vivo.
Kappa selective agonists produce analgesia accompanied by some dysphoric effects [5] and this property limited their therapeutic development. However, mixed mu/kappa agonists (such as ethylketazocine) display fewer side-effects than their kappa-selective counterparts such as enadoline and spiradoline [6, 7] and have been used to treat cocaine addiction [8] . Presumably, the effects produced by muagonists help attenuate the dysphoric action associated with kappa agonism.
A combination of buprenorphine (a partial mu agonist/kappa antagonist) and naltrexone (a non-selective antagonist) produced antidepressant-like activity in mice and may represent a novel approach in the treatment of depression [9] . The synthesis of mixed mu/kappa receptor antagonists, combining these two activities in one compound, would overcome the abuse liability issue and also the issue of a proper dosing ratio of two separate entities. A new orvinol analog BU10119 with the mu/kappa antagonist affinity profile has recently been obtained by Cueva et al. [10] . In vitro BU 10119 showed high affinity for kappa and mu receptors with little efficacy at both these receptors, indicating an antagonist-like profile. The initial characterization of this analog in vivo in mouse models of depression showed the therapeutic potential of BU 10119 for the treatment of depression and other stressinduced conditions [11] .
In 1991 Abdelhamid et al. [12] demonstrated for the first time that selective delta opioid receptor blockade with naltrindole (delta opioid antagonist) greatly reduced the development of morphine tolerance and dependence in mice. Opioid ligands combining mu agonist/delta antagonist activity in one compound were therefore sought for the development of analgesics with lower propensity to produce tolerance and physical dependence [13] .
The first known compound with mixed mu agonist/delta antagonist profile was the tetrapeptide amide Tyr-Tic-Phe-Phe-NH 2 (TIPP-NH 2 , were Tic represents 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) [14] . TIPP-NH 2 showed quite high delta antagonist but modest mu agonist potency. Further modifications including replacement of Tyr 1 residue by Dmt (Dmt = 2′,6′-dimethyltyrosine) and a reduction of the peptide bond between Tic 2 and Phe 3 led to a pseudopeptide Dmt-
) with greatly improved mu potency. As expected, this analog exhibited reduced tolerance compared to morphine and no dependence, when administered intracerebroventricularly [15] . However, the therapeutic potential of DIPP-NH 2 [ψ] was compromised by its poor blood-brain barrier (BBB) permeability [16] . Purington et al. [17] reported the synthesis of a cyclic tetrapeptide KSK-103, containing a S-CH 2 -CH 2 -S-bridge that showed equal and high affinity for mu and delta receptors but, similar to the previously reported ligands, had poor bioavailability. Glycosylation of this cyclopeptide produced an analog that retained the desirable in vitro profile, while displaying centrally mediated antinociception after intraperitoneal (i.p.) injection with a potency similar to morphine [18] .
It was also shown that potency and efficacy of the mu agonists can be enhanced by delta agonists. Synergistic antinociceptive effects in response to the mu and delta receptor activation were observed in several in vivo studies. For example, enkephalins, DPDPE or deltorphine potentiated antinociceptive effect of morphine [19] [20] [21] [22] . These results pointed at a functional interaction between mu and delta opioid receptors and a potential regulatory role of the endogenous delta ligands in controlling pain.
Therefore, the search for single compounds combining mixed mu/ delta agonist activities followed. The best know and the most studied peptide ligand with the dual mu/delta agonist profile is biphalin [Tyr-DAla-Gly-Phe-NH-NH-Phe-Gly-D-Ala-Tyr], whose structure is based on two enkephalin-like fragments connected "tail-to-tail" by a hydrazine bridge [23] . Biphalin showed high affinity for the mu and delta receptors (with K i about 1-4 nM), very good antinociceptive activity and duration of action after intrathecal (i.t.) administration [24] , induced less physical dependence than morphine [25] and could penetrate the BBB [26] . Several linear analogs of biphalin with amino acid substitutions in positions 2,2′ and 4,4′ were also reported [27, 28] .
To overcome moderate stability of biphalin in human plasma [29] the group of Mollica developed several cyclic analogs of biphalin with a disulfide linkage [30, 31] or a xylene bridge [32] . Such analogs showed increased in vitro affinity for the mu and delta receptors and prolonged in vivo antinociceptive effect [33, 34] .
In our earlier paper we described a cyclic tetrapeptide, Tyr-c[D-LysPhe-Asp]NH 2 [35] , which was highly mu selective. Here, replacement of Tyr by Dmt resulted in obtaining an analog with mu/delta profile and very high potency for these two receptors. The pharmacological profile of this cyclopeptide was investigated in detail, both in vitro and in vivo.
Materials and methods

Materials
Peptide synthesis reagents (amino acids, MBHA Rink-Amide resin, TBTU) were purchased from Bachem AG (Bubendorf, Switzerland 
Peptide synthesis
Peptides were synthesized on solid support, using Fmoc chemistry as described elsewhere [36] . Crude peptides were purified using a Waters semipreparative HPLC (Waters Breeze instrument, Milford, MA, USA) with a Vydac C 18 column (10 μm, 22 × 250 mm), using the solvent system of 0.1% TFA in water (A)/80% acetonitrile in water containing 0.1% TFA (B). A linear gradient of 0-100% B over 50 min at a flow rate of 1 mL/min was used. The molecular weight of peptides was confirmed by ESI-MS recorded on Bruker micrOTOF-Q mass spectrometer (Bruker Daltonics, Bremen, Germany). The purity of the cyclopeptides was verified by analytical HPLC employing a Vydac C18 column (5 μm, 4.6 × 250 mm) and the solvent system of 0.1% TFA in water (A)/80% acetonitrile in water containing 0.1% TFA (B). All peptides were at least 96% pure as determined by HPLC monitored at 230 nm.
Radioligand binding assays
Radioligand binding assays were performed according to the previously described method [37] using commercial membranes of Chinese Hamster Ovary (CHO) cells transfected with human opioid receptors. The binding affinities for mu, delta and kappa opioid receptors were determined by radioligand competition analysis using 
Calcium mobilization assay
Calcium mobilization assay was performed as reported in detail elsewhere [39] , using CHO cells stably co-expressing human recombinant mu or kappa opioid receptors and the C-terminally modified Gα qi5 and CHO cells co-expressing the human recombinant delta opioid receptor and the Gα qG66Di5 chimeric protein.
Agonist potencies of peptides are given as pEC 50 that is the negative logarithm of the molar concentration of an agonist that produces 50% of the maximal possible effect. Ligand efficacy was expressed as intrinsic activity (α).
Bioluminescence resonance energy transfer (BRET) assay
BRET assay was described in our earlier paper [40] . SH-SY5Y cell lines permanently co-expressing mu-RLuc and one of the transduction protein (Gβ 1 -RGFP or β-arrestin 2-RGFP) were used to determine the interaction of the mu receptor with G-protein and β-arrestin 2. Methods for cell culturing, retroviral transduction, and BRET assay have been described previously [41, 42] . Agonist responses were quantified as stimulated BRET ratio obtained by subtracting the vehicle value from that measured in the presence of the ligand.
For calculation of bias factors EM-2 was used as a standard unbiased ligand.
The concentration response curves of each compound were fitted to the Black-Leff operational model described by Nagi et al. [43] :
n n m n n A n where [A] is the agonist concentration, the maximal response of the system is given by E m , n is a fitting parameter for the slope, the affinity of the agonist is represented by the equilibrium dissociation constant of the agonist-receptor complex (K A ), and the efficacy of the agonist is defined by τ. K A and τ are descriptive parameters of intrinsic efficacy and binding affinity and may be directly obtained by fitting experimental data to the operational equation and can be expressed as "transduction coefficients" log(τ/K A ). The relative efficiency of an agonist producing activation of any pathway can thus be quantified with a "normalized" transduction coefficient, namely Δlog(τ/K A ). Finally, the bias factor was calculated as a difference between Δlog(τ/K A ) values for a given agonist between the pathways (G protein and β-arrestin 2):
Bias factors are expressed as the mean ± SEM of at least 5 independent experiments.
In vitro activity in isolated smooth muscle strips
Organ bath studies were performed as described previously [44] . Mice were sacrificed by cervical dislocation. The colon was rapidly removed and 0.5 cm long full-thickness fragments were distincted. Preparations were kept in cold oxygenated Krebs-Ringer Solution. Electrical field stimulation (EFS; 4 Hz, 24 V, stimulus duration 0.5 ms, train duration 10 s) was applied using a S88X stimulator (Grass Technologies, West Warwick, RI, USA). A tested compound at increasing concentrations (10 −12 to 10 −6 M) was added cumulatively into the organ bath. Tissue was incubated with each concentration for 8 min. As an internal control, the mean amplitude of initial 3 successive contractions was used. Changes in contractility (after a tested compound addition) were measured and reported as percentage of internal control.
Animal tests 2.7.1. Animals
Male Balb/C mice (Institute of Occupational Medicine, Lodz, Poland), weighing 22-24 g, were used for the study. The animals were housed in a room with controlled temperature (22 ± 1°C), humidity (70 ± 5%) and light/dark cycle conditions (12/12 h), with free access to laboratory chow and tap water. All procedures were approved by the Local Ethical Committee for Animal Research with the following numbers: 29/ŁB662/2013 and 20/ŁB708/2014.
Drugs and pharmacological treatment
The tested compounds were dissolved in DMSO, further diluted with 0.9% NaCl solution to the final concentration of 5% DMSO. Animals without treatment (control group) received vehicle alone (5% DMSO in 0.9% NaCl solution). The vehicle given alone had no effects on the observed parameters.
Assessment of antinociception
The antinociceptive effects of peptides were assessed in the hotplate test in mice as described earlier [45] . [46] . The data were analyzed by a nonlinear least square regression analysis computer program Graph Pad PRISM 6.0 (GraphPad Software Inc., San Diego, USA).
Evaluation of whole gastrointestinal transit
Whole gastrointestinal transit (WGT) test in mice was performed as described [47] . A tested compound was injected i.p. (in the final volume of 0.1 mL) 15 min before intragastric (i.g.) administration of a colored marker (0.15 mL of glutinous liquid consisting of 5% Evans blue and 5% Arabic gum). The colored dye was administered with 18-gauge animal feeding tube. Subsequently, mice were placed in the individual cages on a white sheet of paper (in order to facilitate recognition of colored boluses). The whole gastrointestinal transit is calculated as time between i.g. administration of the marker and excretion of the first colored bolus.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA). All data are expressed as mean ± SEM Analysis of multiple treatment was performed using one way analysis of variance (ANOVA) followed by Newman-Keuls post-hoc test. P values < 0.05 were considered statistically significant. Table 1 . Introduction of Dmt resulted in transforming a mu selective analog 1 into a peptide 2 with very high affinity for mu and delta receptors.
Results
In vitro profile of
The pharmacological profile of the new analog was further evaluated in vitro at all three opioid receptors in the calcium mobilization [51] [52] [53] [54] [55] [56] [57] assay in which CHO cells expressing human recombinant opioid receptors and chimeric G proteins were used to monitor calcium changes. The concentration-response curves of the tested compounds and the standards were obtained and the calculated agonist potencies (pEC 50 ) and efficacies (α) are shown in Table 2 . At the mu receptor analog 2 displayed even higher potency than the reference mu agonist, endomorphin-2 (EM-2) and the same maximal effect. At the delta receptor 2 showed the same potency and maximal effect as the selective delta agonist DPDPE. Compared to dynorphin A, the kappa receptor reference compound, cyclopeptide 2 displayed very low potency and reduced efficacy. In agreement with the binding assay results, introduction of Dmt transformed analog 1 with high mu potency into a nonselective peptide 2 which showed high potency at the mu and delta receptors. Then, the interaction of the mu opioid receptor with G-protein and β-arrestin 2 were evaluated in the BRET assay, measuring the energy transfer between Renilla Luciferase (RLuc) linked to the mu opioid receptor and Renilla Green Fluorescent Protein (RGFP) linked to the signal transducer proteins (G-protein or β-arrestin 2). In membrane extracts taken from SH-SY5Y cells co-expressing the mu/RLuc and the Gβ 1 -RGFP fusoproteins, the mu receptor agonist EM-2 promoted receptor/G protein interaction in a concentration dependent manner with potency value of 6.97 and maximal effect (E max ) of 0.80 ± 0.11 stimulated BRET ratio (Fig. 1A) . Analog 1 mimicked the maximal effects of EM-2, being 4 fold more potent (Fig. 1B) . In a separate series of experiments, EM-2 promoted mu/G-protein interaction in a concentration-dependent manner with high potency (pEC 50 7.32 ) and maximal effect of 1.48 ± 0.16 stimulated BRET ratio (Fig. 1C) . Under the same experimental conditions cyclopeptide 2 behaved as a full agonist and was 8 fold more potent than EM-2 (Fig. 1D) .
In SH-SY5Y cells stably co-expressing the mu/RLuc and the β-arrestin 2/RGFP fusoproteins, EM-2 promoted receptor/arrestin interaction in a concentration dependent manner with a potency value of 6.91, and E max of 0.35 ± 0.09 stimulated BRET ratio (Fig. 1A) . Analog 1 showed higher maximal effects and was 4 fold more potent than EM-2 (Fig. 1B) . In the second series of experiments, EM-2 promoted mu/β-arrestin interaction in a concentration dependent manner with a potency value of 7.20, and E max of 0.38 ± 0.04 stimulated BRET ratio (Fig. 1C) . Compound 2 was 16 fold more potent and exhibited higher maximal effect than EM-2 (Fig. 1D) . These results, which are shown in Fig. 1 , were used for calculating bias factors of the ligands: analog 1 had a bias factor not statistically different from 0, while analog 2 displayed a modest (14-fold) but significant bias toward β-arrestin 2 (Table 3) .
In further in vitro experiments, the effect of analog 2 was evaluated on EFS-induced smooth muscle contractility in the mouse distal colon. Analog 2 significantly inhibited EFS-induced colonic contractions in a concentration-dependent manner (10 −9 to 10 −6 M) (Fig. 2) .
In vivo profile of cyclopeptide analogs
Assessment of antinociception of cyclopeptide analogs was studied in the mouse hot-plate test (supraspinally mediated analgesia), after i.c.v. administration. Both compounds showed an extremely strong analgesic effect, which was dose-dependent (Fig. 3 ). Analog 2 with the mu/delta profile exerted stronger antinociceptive effect than the parent compound 1, which was mu selective. The ED 50 were 0.6 ng and 2.9 ng for analog 2 and analog 1, respectively.
The antinoceptive activity of analog 2 was effectively reversed by preemptive i.c.v. injection of β-FNA (mu selective antagonist) or NLT (delta selective antagonist) (Fig. 4) , indicating that the action of this peptide was mediated by the mu and delta opioid receptors in the brain.
To compare the inhibitory effect of analogs 1 and 2 on gastrointestinal (GI) transit, the mouse WGT test was performed. Tested compounds were administered at three doses (0.1; 0.3; and 1 mg/kg, i.p.) For comparison, loperamide, the well-known antidiarrheal agent, was used. Analog 2 with biased profile toward β-arrestin 2/mu exerted the strongest effect. This compound significantly decreased the WGT at all three concentrations. At a dose of 0.1 mg/kg, it delayed excretion of the colored boluses up to 193.7 ± 24.7 min, in comparison to control (90.9 ± 5.0 min) and loperamide (130.0 ± 3.0 min). Analog 1 and loperamide were active only at the highest used dose, which was 1 mg/ kg (Fig. 5 ).
Discussion
Most of the currently available pain-relieving opioids exert their analgesic but also adverse effects primarily through the activation of the mu receptor. However, a large number of biochemical and pharmacological studies provide evidence that there are strong modulatory interactions between mu and delta opioid receptors. Several studies indicate that delta receptor agonists as well as antagonists can significantly improve the pharmacological effects exerted by mu agonists. In particular, delta agonists can enhance the analgesic potency and efficacy of mu agonists, and delta antagonists can prevent or diminish the development of tolerance and physical dependence induced by mu agonists.
Therefore, the use of agents that simultaneously activate more than one opioid receptor in order to enhance efficacy and/or reduce side effects is a promising approach in the search for innovative analgesics [3, 48] .
As is well known, opioid agonists interact with GPCRs which upon activation, are phosphorylated by GPCR kinases and subsequently bind β-arrestins, which prevent further coupling of the receptor to G protein [49] . GPCRs can then be internalized and are either recycled to the plasma membrane or degraded. However, β-arrestins are not only negative regulators of the G protein signaling but can promote distinct intracellular signals of their own. Experiments with the β-arrestin 2 knockout (KO) mice showed that signaling mechanism of morphine The crc incomplete means that the maximal effect could not be determined due to the low potency of a compound. EM-2, DPDPE, and dynorphin A were used as reference agonists for calculating intrinsic activity at the mu, delta and kappa opioid receptors, respectively. a Agonist potency values (pEC 50 ).
b Efficacy values (α).
engage both G protein coupling and β-arrestin recruitment and that blocking the β-arrestin pathway can reduce unwanted side effects of opioids, such as respiratory depression, inhibition of gastrointestinal motility, and tolerance liability. In the β-arrestin 2 KO mice morphine induced, via the mu opioid receptor, enhanced and longer-lasting antinociceptive effects than in a wild type mice and almost no tolerance [50, 51] . On the other hand, the antidiarrheal agent loperamide, which is a peripherally restricted mu receptor agonist, significantly reduced colonic propulsion in wild type mice, and this effect was completely abolished in β-arrestin 2 KO mice [52] . This suggests that peripherally restricted β-arrestin-biased agonists might be useful in the treatment of diarrhea and other hypermotility disorders [53] .
The discovery of β-arrestin-mediated signaling pathways opened new possibilities in opioid drug development [54] [55] [56] . Agonists biased to either G protein or β-arrestin may be used to segregate physiological responses downstream of the receptor [57] [58] [59] .
Molinari et al. [42] measured the possible differential ability of various opioid ligands of peptide and alkaloid structure (including EM-2 and morphine) to induce G-protein and β-arrestin signaling at the mu and delta receptors. None of the tested ligands showed greater efficacy for β-arrestin than for the G-protein. The authors suggested that the structure requirements for an agonist to trigger the interaction of the receptor with β-arrestin are more stringent than those sufficient to initiate G-protein coupling. (2) , activated G protein pathway similarly to EM-2 but promoted β-arrestin recruitment with a much higher maximal effect than EM-2 (1.46 and 1.0, respectively) and therefore showed 14-fold bias toward β-arrestin. To the best of our knowledge, analog 2 is the first reported β-arrestin biased opioid peptide. This ligand activated with high efficacy the mu and delta receptors. Compounds with such profile are known to exert stronger pharmacological effects than the mu selective ligands. Indeed, analog 2 showed a 5-fold more pronounced antinociceptive effect in mice than its mu selective parent 1. On the other hand, 2 was also found to strongly inhibit the WGT in mice which is consistent with activation of the β-arrestin pathway.
These results are in accordance with earlier reports indicating that various in vivo activities of opioid agonists arise not only from the activation of one or more opioid receptors, but also from promoting Gprotein or β-arrestin pathways. Therefore prediction of molecular interactions linked to the drug responses in vivo is very complex.
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